Joao Manuel Santos
Overview
Explore the profile of Joao Manuel Santos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clubb J, Kudling T, Girych M, Haybout L, Pakola S, Hamdan F, et al.
Front Immunol
. 2023 Feb;
14:1060540.
PMID: 36817448
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, but preclinical testing of hypotheses such as combination therapies has been complicated, in part due to species incompatibility issues....
2.
Heinio C, Clubb J, Kudling T, Quixabeira D, Cervera-Carrascon V, Havunen R, et al.
Diseases
. 2022 Aug;
10(3).
PMID: 35997357
Ovarian cancer (OvCa) is one of the most common gynecological cancers and has the highest mortality in this category. Tumors are often detected late, and unfortunately over 70% of OvCa...
3.
Clubb J, Kudling T, Heinio C, Basnet S, Pakola S, Cervera Carrascon V, et al.
Front Immunol
. 2022 Mar;
13:794251.
PMID: 35355980
Immune checkpoint inhibitors (ICI) have provided significant improvement in clinical outcomes for some patients with solid tumors. However, for patients with head and neck cancer, the response rate to ICI...
4.
Milenova I, Lopez Gonzalez M, Quixabeira D, Santos J, Cervera-Carrascon V, Dong W, et al.
Hum Gene Ther
. 2021 Jan;
32(3-4):178-191.
PMID: 33470166
Immune checkpoint inhibitors have advanced the treatment of melanoma. Nevertheless, a majority of patients are resistant, or develop resistance, to immune checkpoint blockade, which may be related to prevailing immune...
5.
Cervera-Carrascon V, Quixabeira D, Santos J, Havunen R, Zafar S, Hemminki O, et al.
Oncoimmunology
. 2020 Sep;
9(1):1761229.
PMID: 32923123
Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to...
6.
Zafar S, Quixabeira D, Kudling T, Cervera-Carrascon V, Santos J, Gronberg-Vaha-Koskela S, et al.
Cancer Gene Ther
. 2020 Sep;
28(5):442-454.
PMID: 32920593
Oncolytic adenoviruses are promising cancer therapeutic agents. Clinical data have shown adenoviruses' ability to transduce tumors after systemic delivery in human cancer patients, despite antibodies. In the present work, we...
7.
Santos J, Havunen R, Hemminki A
Methods Enzymol
. 2020 Mar;
635:205-230.
PMID: 32122546
Despite exciting proof-of-concept data mediated by adoptive T-cell transfer and checkpoint blockade, major challenges imposed by the tumor microenvironment restrict clinical benefits to a minority of patients with advanced or...
8.
Santos J, Heinio C, Cervera-Carrascon V, Quixabeira D, Siurala M, Havunen R, et al.
J Immunother Cancer
. 2020 Jan;
8(1).
PMID: 31940588
Background: Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT). However, the immunosuppressive ovarian tumor microenvironment and lack of...
9.
Lopez Gonzalez M, Oosterhoff D, Lindenberg J, Milenova I, Lougheed S, Martianez T, et al.
Oncoimmunology
. 2019 Oct;
8(10):e1631119.
PMID: 31646076
In patients with cancer, the functionality of Dendritic Cells (DC) is hampered by high levels of tumor-derived suppressive cytokines, which interfere with DC development and maturation. Poor DC development can...
10.
Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, et al.
Oncoimmunology
. 2018 Nov;
7(10):e1490856.
PMID: 30386680
Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer immunotherapy in...